...
search icon
aapg-img

Ascentage Pharma Group International, Common Stock

AAPG

NMQ

$42.85

+$3

(7.53%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.45B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.00
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$16.5 L
$40.81 H
$42.85

About Ascentage Pharma Group International, Common Stock

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAAPGSectorS&P500
1-Week Return5%0.95%1.09%
1-Month Return54.41%1.86%4.07%
3-Month Return85.74%-5.33%15.41%
6-Month Return146.55%-2.49%4.76%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue12.45M4.33M209.71M221.98M980.65M[{"date":"2020-12-31","value":1.27,"profit":true},{"date":"2021-12-31","value":0.44,"profit":true},{"date":"2022-12-31","value":21.38,"profit":true},{"date":"2023-12-31","value":22.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue1.97M3.33M22.00M30.54M29.09M[{"date":"2020-12-31","value":6.44,"profit":true},{"date":"2021-12-31","value":10.9,"profit":true},{"date":"2022-12-31","value":72.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":95.23,"profit":true}]
Gross Profit10.48M24.58M187.71M191.44M951.57M[{"date":"2020-12-31","value":1.1,"profit":true},{"date":"2021-12-31","value":2.58,"profit":true},{"date":"2022-12-31","value":19.73,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin84.21%568.03%89.51%86.24%97.03%[{"date":"2020-12-31","value":14.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":15.76,"profit":true},{"date":"2023-12-31","value":15.18,"profit":true},{"date":"2024-12-31","value":17.08,"profit":true}]
Operating Expenses674.42M894.42M1.04B1.06B1.32B[{"date":"2020-12-31","value":51.04,"profit":true},{"date":"2021-12-31","value":67.69,"profit":true},{"date":"2022-12-31","value":78.52,"profit":true},{"date":"2023-12-31","value":80.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(663.94M)(869.84M)(849.81M)(872.64M)(369.73M)[{"date":"2020-12-31","value":-66394100000,"profit":false},{"date":"2021-12-31","value":-86983500000,"profit":false},{"date":"2022-12-31","value":-84981000000,"profit":false},{"date":"2023-12-31","value":-87263600000,"profit":false},{"date":"2024-12-31","value":-36973000000,"profit":false}]
Total Non-Operating Income/Expense(12.54M)27.96M(80.42M)(123.87M)(52.14M)[{"date":"2020-12-31","value":-44.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-287.61,"profit":false},{"date":"2023-12-31","value":-443.02,"profit":false},{"date":"2024-12-31","value":-186.47,"profit":false}]
Pre-Tax Income(675.45M)(832.25M)(887.17M)(932.86M)(395.25M)[{"date":"2020-12-31","value":-67544800000,"profit":false},{"date":"2021-12-31","value":-83224900000,"profit":false},{"date":"2022-12-31","value":-88717200000,"profit":false},{"date":"2023-12-31","value":-93286200000,"profit":false},{"date":"2024-12-31","value":-39525500000,"profit":false}]
Income Taxes2.16M(49.83M)(4.25M)(7.15M)10.43M[{"date":"2020-12-31","value":20.7,"profit":true},{"date":"2021-12-31","value":-477.94,"profit":false},{"date":"2022-12-31","value":-40.75,"profit":false},{"date":"2023-12-31","value":-68.59,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(677.61M)(782.42M)(882.92M)(925.71M)(405.68M)[{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92571200000,"profit":false},{"date":"2024-12-31","value":-40568000000,"profit":false}]
Income From Continuous Operations(677.61M)(782.42M)(882.92M)(925.71M)(405.68M)[{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92571200000,"profit":false},{"date":"2024-12-31","value":-40568000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(677.61M)(782.42M)(882.92M)(925.64M)(405.43M)[{"date":"2020-12-31","value":-67760600000,"profit":false},{"date":"2021-12-31","value":-78242400000,"profit":false},{"date":"2022-12-31","value":-88292400000,"profit":false},{"date":"2023-12-31","value":-92563700000,"profit":false},{"date":"2024-12-31","value":-40543300000,"profit":false}]
EPS (Diluted)-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

AAPG
Cash Ratio 1.06
Current Ratio 1.26
Quick Ratio 1.26

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

AAPG
ROA (LTM) -7.14%
ROE (LTM) -52.38%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

AAPG
Debt Ratio Lower is generally better. Negative is bad. 0.90
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.10

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

AAPG
Trailing PE NM
Forward PE NM
P/S (TTM) 7.03
P/B 60.58
Price/FCF NM
EV/R 13.44
EV/Ebitda NM

FAQs

What is Ascentage Pharma Group International share price today?

Ascentage Pharma Group International (AAPG) share price today is $42.85

Can Indians buy Ascentage Pharma Group International shares?

Yes, Indians can buy shares of Ascentage Pharma Group International (AAPG) on Vested. To buy Ascentage Pharma Group International from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AAPG stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Ascentage Pharma Group International be purchased?

Yes, you can purchase fractional shares of Ascentage Pharma Group International (AAPG) via the Vested app. You can start investing in Ascentage Pharma Group International (AAPG) with a minimum investment of $1.

How to invest in Ascentage Pharma Group International shares from India?

You can invest in shares of Ascentage Pharma Group International (AAPG) via Vested in three simple steps:

  • Click on Sign Up or Invest in AAPG stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Ascentage Pharma Group International shares
What is Ascentage Pharma Group International 52-week high and low stock price?

The 52-week high price of Ascentage Pharma Group International (AAPG) is $40.81. The 52-week low price of Ascentage Pharma Group International (AAPG) is $16.5.

What is Ascentage Pharma Group International price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Ascentage Pharma Group International (AAPG) is 60.58

What is the Market Cap of Ascentage Pharma Group International?

The market capitalization of Ascentage Pharma Group International (AAPG) is $3.45B

What is Ascentage Pharma Group International’s stock symbol?

The stock symbol (or ticker) of Ascentage Pharma Group International is AAPG

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top